This review aims to explore the relationship and mechanism between Lp(a) and CAVD, and focuses on the current drugs that can be used as potential therapeutic targets for CAVD. This evidence concerns the gene LPA and congenital bilateral aplasia of vas deferens from CFTR mutation.